123 related articles for article (PubMed ID: 37749607)
1. The PTX3/TLR4 autocrine loop as a novel therapeutic target in triple negative breast cancer.
Giacomini A; Turati M; Grillo E; Rezzola S; Ghedini GC; Schuind AC; Foglio E; Maccarinelli F; Faletti J; Filiberti S; Chambery A; Valletta M; Melocchi L; Gofflot S; Chiavarina B; Turtoi A; Presta M; Ronca R
Exp Hematol Oncol; 2023 Sep; 12(1):82. PubMed ID: 37749607
[TBL] [Abstract][Full Text] [Related]
2. Calycosin inhibits triple-negative breast cancer progression through down-regulation of the novel estrogen receptor-α splice variant ER-α30-mediated PI3K/AKT signaling pathway.
Li Y; Hu S; Chen Y; Zhang X; Gao H; Tian J; Chen J
Phytomedicine; 2023 Sep; 118():154924. PubMed ID: 37393829
[TBL] [Abstract][Full Text] [Related]
3. Disruption of the pentraxin 3/CD44 interaction as an efficient therapy for triple-negative breast cancers.
Hsiao YW; Chi JY; Li CF; Chen LY; Chen YT; Liang HY; Lo YC; Hong JY; Chuu CP; Hung LY; Du JY; Chang WC; Wang JM
Clin Transl Med; 2022 Jan; 12(1):e724. PubMed ID: 35090088
[TBL] [Abstract][Full Text] [Related]
4. Cancer cell-derived long pentraxin 3 (PTX3) promotes melanoma migration through a toll-like receptor 4 (TLR4)/NF-κB signaling pathway.
Rathore M; Girard C; Ohanna M; Tichet M; Ben Jouira R; Garcia E; Larbret F; Gesson M; Audebert S; Lacour JP; Montaudié H; Prod'Homme V; Tartare-Deckert S; Deckert M
Oncogene; 2019 Jul; 38(30):5873-5889. PubMed ID: 31253871
[TBL] [Abstract][Full Text] [Related]
5. Excellent effects and possible mechanisms of action of a new antibody-drug conjugate against EGFR-positive triple-negative breast cancer.
Zhou DD; Bai WQ; Zhai XT; Sun LP; Zhen YS; Li ZR; Miao QF
Mil Med Res; 2021 Dec; 8(1):63. PubMed ID: 34879870
[TBL] [Abstract][Full Text] [Related]
6. The oncogenic kinase NEK2 regulates an RBFOX2-dependent pro-mesenchymal splicing program in triple-negative breast cancer cells.
Naro C; De Musso M; Delle Monache F; Panzeri V; de la Grange P; Sette C
J Exp Clin Cancer Res; 2021 Dec; 40(1):397. PubMed ID: 34930366
[TBL] [Abstract][Full Text] [Related]
7. Focal Adhesion Kinase (FAK)-Hippo/YAP transduction signaling mediates the stimulatory effects exerted by S100A8/A9-RAGE system in triple-negative breast cancer (TNBC).
Rigiracciolo DC; Nohata N; Lappano R; Cirillo F; Talia M; Adame-Garcia SR; Arang N; Lubrano S; De Francesco EM; Belfiore A; Gutkind JS; Maggiolini M
J Exp Clin Cancer Res; 2022 Jun; 41(1):193. PubMed ID: 35655319
[TBL] [Abstract][Full Text] [Related]
8. EP300 knockdown reduces cancer stem cell phenotype, tumor growth and metastasis in triple negative breast cancer.
Ring A; Kaur P; Lang JE
BMC Cancer; 2020 Nov; 20(1):1076. PubMed ID: 33167919
[TBL] [Abstract][Full Text] [Related]
9. Landscape of toll-like receptors expression in tumor microenvironment of triple negative breast cancer (TNBC): Distinct roles of TLR4 and TLR8.
Roychowdhury A; Jondhale M; Saldanha E; Ghosh D; Kumar Panda C; Chandrani P; Mukherjee N
Gene; 2021 Aug; 792():145728. PubMed ID: 34022297
[TBL] [Abstract][Full Text] [Related]
10. CIP2A is a target of bortezomib in human triple negative breast cancer cells.
Tseng LM; Liu CY; Chang KC; Chu PY; Shiau CW; Chen KF
Breast Cancer Res; 2012 Apr; 14(2):R68. PubMed ID: 22537901
[TBL] [Abstract][Full Text] [Related]
11. Knockdown of nucleophosmin 1 suppresses proliferation of triple-negative breast cancer cells through activating CDH1/Skp2/p27kip1 pathway.
Zeng D; Xiao Y; Zhu J; Peng C; Liang W; Lin H
Cancer Manag Res; 2019; 11():143-156. PubMed ID: 30613163
[TBL] [Abstract][Full Text] [Related]
12. Increase in ADAR1p110 activates the canonical Wnt signaling pathway associated with aggressive phenotype in triple negative breast cancer cells.
Morales F; Pérez P; Tapia JC; Lobos-González L; Herranz JM; Guevara F; de Santiago PR; Palacios E; Andaur R; Sagredo EA; Marcelain K; Armisén R
Gene; 2022 Apr; 819():146246. PubMed ID: 35122924
[TBL] [Abstract][Full Text] [Related]
13. Tryptophan hydroxylase 1 and 5-HT
Gautam J; Banskota S; Regmi SC; Ahn S; Jeon YH; Jeong H; Kim SJ; Nam TG; Jeong BS; Kim JA
Mol Cancer; 2016 Nov; 15(1):75. PubMed ID: 27871326
[TBL] [Abstract][Full Text] [Related]
14. microRNA-761 induces aggressive phenotypes in triple-negative breast cancer cells by repressing TRIM29 expression.
Guo GC; Wang JX; Han ML; Zhang LP; Li L
Cell Oncol (Dordr); 2017 Apr; 40(2):157-166. PubMed ID: 28054302
[TBL] [Abstract][Full Text] [Related]
15. The IL1β-IL1R signaling is involved in the stimulatory effects triggered by hypoxia in breast cancer cells and cancer-associated fibroblasts (CAFs).
Lappano R; Talia M; Cirillo F; Rigiracciolo DC; Scordamaglia D; Guzzi R; Miglietta AM; De Francesco EM; Belfiore A; Sims AH; Maggiolini M
J Exp Clin Cancer Res; 2020 Aug; 39(1):153. PubMed ID: 32778144
[TBL] [Abstract][Full Text] [Related]
16. Notch-Mediated Tumor-Stroma-Inflammation Networks Promote Invasive Properties and CXCL8 Expression in Triple-Negative Breast Cancer.
Liubomirski Y; Lerrer S; Meshel T; Morein D; Rubinstein-Achiasaf L; Sprinzak D; Wiemann S; Körner C; Ehrlich M; Ben-Baruch A
Front Immunol; 2019; 10():804. PubMed ID: 31105691
[TBL] [Abstract][Full Text] [Related]
17. Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat.
Tate CR; Rhodes LV; Segar HC; Driver JL; Pounder FN; Burow ME; Collins-Burow BM
Breast Cancer Res; 2012 May; 14(3):R79. PubMed ID: 22613095
[TBL] [Abstract][Full Text] [Related]
18. Tumor-Stroma-Inflammation Networks Promote Pro-metastatic Chemokines and Aggressiveness Characteristics in Triple-Negative Breast Cancer.
Liubomirski Y; Lerrer S; Meshel T; Rubinstein-Achiasaf L; Morein D; Wiemann S; Körner C; Ben-Baruch A
Front Immunol; 2019; 10():757. PubMed ID: 31031757
[TBL] [Abstract][Full Text] [Related]
19. Coordinated regulation of WNT/β-catenin, c-Met, and integrin signalling pathways by miR-193b controls triple negative breast cancer metastatic traits.
Giacomelli C; Jung J; Wachter A; Ibing S; Will R; Uhlmann S; Mannsperger H; Sahin Ö; Yarden Y; Beißbarth T; Korf U; Körner C; Wiemann S
BMC Cancer; 2021 Dec; 21(1):1296. PubMed ID: 34863149
[TBL] [Abstract][Full Text] [Related]
20. Guanylate-binding protein-1 is a potential new therapeutic target for triple-negative breast cancer.
Quintero M; Adamoski D; Reis LMD; Ascenção CFR; Oliveira KRS; Gonçalves KA; Dias MM; Carazzolle MF; Dias SMG
BMC Cancer; 2017 Nov; 17(1):727. PubMed ID: 29115931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]